ImageneBio, Inc. Cash Flow Statement
IMA|5 years of annual SEC 10-K data (FY2021-FY2025)
Covers operating cash flow, capital expenditures, free cash flow, share buybacks, and dividends paid across 5 fiscal years. All figures from audited SEC 10-K filings.
ImageneBio, Inc. used $21M in operating cash flow in FY2025.
Based on SEC 10-K filings.
Key Data Points
- Altman Z-Score -0.34 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Net Income | -$36.6M | -$68.2M | -$68.8M | -$34.1M | -$44.3M |
| Depreciation & Amortization | $1.1M | $1.0M | $751.0K | $544.0K | $300.0K |
| Operating Cash Flow | -$21.3M | -$79.7M | -$74.1M | -$60.3M | -$37.8M |
| Capital Expenditures | - | $414.0K | $1.4M | $1.8M | $766.0K |
| Free Cash Flow | - | -$80.2M | -$75.5M | -$62.0M | -$38.6M |
| Share Buybacks | - | $663.0K | $663.0K | - | - |
| FCF Margin | - | -875.1% | -483.7% | -200.1% | -419.8% |